Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of the ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

Drugs such as Mounjaro and Zepbound (the generic name is tirzepatide ... but are also effective as weight-loss drugs. But GLP-1 users may have to stay on them long-term to maintain their weight ...

Eli Lilly reassures investors about strong demand for its weight-loss and diabetes drugs, Zepbound and Mounjaro. Despite supply chain issues and lower-than-expected sales, the company expects ...

Sales of the company's blockbuster weight-loss drugs Mounjaro and Zepbound grew to $3.53 billion and $1.91 billion, respectively, below expectations of $3.65 billion and $2.04 billion. Eli Lilly ...

The company said last month that it expected to report sales of diabetes drug Mounjaro and weight-loss treatment Zepbound below analysts' expectations for a second quarter in a row. The US ...